Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $86.5 million.

  • Century Therapeutics' Shares Outstanding (Diluted Average) rose 207.75% to $86.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.5 million, marking a year-over-year increase of 207.75%. This contributed to the annual value of $78.6 million for FY2024, which is 3259.68% up from last year.
  • Per Century Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $86.5 million for Q3 2025, which was up 207.75% from $86.2 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Shares Outstanding (Diluted Average) registered a high of $86.5 million during Q3 2025, and its lowest value of $32.4 million during Q4 2022.
  • Over the past 4 years, Century Therapeutics' median Shares Outstanding (Diluted Average) value was $59.4 million (recorded in 2023), while the average stood at $67.2 million.
  • As far as peak fluctuations go, Century Therapeutics' Shares Outstanding (Diluted Average) soared by 8311.12% in 2023, and later soared by 207.75% in 2025.
  • Century Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $32.4 million in 2022, then soared by 83.11% to $59.3 million in 2023, then skyrocketed by 32.6% to $78.6 million in 2024, then grew by 9.94% to $86.5 million in 2025.
  • Its last three reported values are $86.5 million in Q3 2025, $86.2 million for Q2 2025, and $86.1 million during Q1 2025.